The novel selective TLR7 agonist GY101 suppresses colon cancer growth by stimulating immune cells

Toll-like receptor (TLR) 7, a transmembrane signal transduction receptor expressed on the surface of endosomes, has become an attractive target for antiviral and cancer immunotherapies. TLR7 can induce signal transduction by recognizing single-stranded RNA or its analogs, leading to the release of c...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	European journal of pharmacology 2024-03, Vol.967, p.176383-176383, Article 176383
Hauptverfasser:	Ren, Su-mei, Chang, Jun-biao, Liu, Rui-qi, Jin, Guang-yi
Format:	Artikel
Sprache:	eng
Schlagworte:	Adjuvants, Immunologic Animals Colon cancer Colonic Neoplasms - drug therapy Immunotherapy Interleukin-12 Interleukin-6 Lymphocytes Mice TLR7 agonist Toll-Like Receptor 7 - agonists Tumor Necrosis Factor-alpha Tumor-associated macrophages
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!